Form D · Biotechnology
Retrotope, Inc.
Los Altos, CA · CIK 0001607677
Offering snapshot reported May 13, 2021 · SEC filing
- Reported sold
- $25.5M Offering amount: $58.3M
- Investors reported
- 39 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 14, 2020 As reported in this filing
Fundraising history
Reported soldDates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.
What changed?
Latest filing versus its linked predecessor, where available.
- Reported sold$13,298,500 → $25,537,307
- Reported investors25 → 39
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 13, 2021 | Amendment | $25,537,307 | $12,238,807vs Jan 15, 2021 | 39 | SEC filing |
| Jan 15, 2021 | Amendment | $13,298,500 | $411,500vs Dec 15, 2020 | 25 | SEC filing |
| Dec 15, 2020 | Amendment | $12,887,000 | $2,787,000vs Aug 28, 2020 | 21 | SEC filing |
| Aug 28, 2020 | Initial | $10,100,000 | No comparison | 3 | SEC filing |
| Jul 30, 2019 | Initial | $4,067,933 | No comparison | 28 | SEC filing |
| Jul 12, 2019 | Amendment | $20,000,000 | $11,950,736vs May 15, 2019 | 37 | SEC filing |
| May 15, 2019 | Amendment | $8,049,264 | $2,814,999vs Feb 27, 2019 | 20 | SEC filing |
| Feb 27, 2019 | Amendment | $5,234,265 | $2,234,265vs Dec 13, 2018 | 14 | SEC filing |
| Dec 13, 2018 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
| Dec 13, 2018 | Initial | $4,330,506 | No comparison | 40 | SEC filing |
| Jan 3, 2018 | Initial | $2,350,000 | No comparison | 16 | SEC filing |
| Nov 29, 2016 | Initial | $2,727,869 | No comparison | 26 | SEC filing |
| Mar 25, 2016 | Amendment | $14,532,456 | $8,203,456vs Aug 19, 2014 | 66 | SEC filing |
| Jan 20, 2015 | Amendment | $9,955,500 | $156,500vs Oct 22, 2014 | 46 | SEC filing |
| Oct 22, 2014 | Amendment | $9,799,000 | $3,470,000vs Aug 19, 2014 | 43 | SEC filing |
| Aug 19, 2014 | Amendment | $6,329,000 | $520,000vs May 21, 2014 | 28 | SEC filing |
| May 21, 2014 | Initial | $5,809,000 | No comparison | 24 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-374390
Source: Form D, filed May 13, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ernst Guenter Afting | Director |
| Timur Artemev | Director |
| Charles Cantor | Director, Executive |
| George Garibaldi | Director |
| Robert F. Johnston | Director |
| Yvonne Kao | Executive |
| Anil Kumar | Director, Executive |
| Corey Mc Cann | Director |
| Nitin Mehta | Director |
| Peter Milner | Director |
| Robert Molinari | Director |
| Harry Saal | Director |
| Mikhail Shchepinov | Director, Executive |
| Leonardus H.T. Van Der Ploeg | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4300 El Camino Real, Suite 201
Los Altos, CA, 94022
Los Altos, CA, 94022